Cancer Cachexia Market Size, Share and Growth Outlook, 2026

Cancer Cachexia Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer Cachexia Market size is forecast to increase from $2.6 Billion in 2026 to $3.53 Billion in 2034 at a CAGR of 3.9% between 2026 and 2034.

The Cancer Cachexia market report provides detailed analysis and outlook of Cancer Cachexia segments including By Product (Progestogens, Corticosteroids, Combination Therapies, Anabolic Steroids & SARMs, Nutritional Supplements & Medical Foods), By Mechanism of Action (Appetite Stimulants, Myostatin Inhibitors, Ghrelin Receptor Agonists, Anti-inflammatory Agents), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Cancer Treatment Centers, Hospitals, Homecare Settings, Palliative Care Facilities) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer Cachexia Industry Overview

Targeted GDF-15 Inhibition Advancing Cancer Cachexia Therapeutics

The cancer cachexia industry is witnessing significant therapeutic innovation through the development of targeted treatments designed to address the biological drivers of cancer-associated weight loss and muscle wasting. Pfizer has expanded its clinical development activities through the initiation of the RIVER-mPDAC trial, a global randomized, double-blind Phase 2b/3 study evaluating ponsegromab in patients with cancer cachexia and metastatic pancreatic ductal adenocarcinoma. The investigational humanized monoclonal antibody specifically targets growth differentiation factor 15 (GDF-15), a key mediator of appetite suppression and metabolic dysfunction in cachexia. The study is expected to enroll approximately 1,000 patients and will evaluate changes in total body weight alongside improvements in appetite-related symptoms while patients receive standard first-line chemotherapy regimens. This large-scale clinical program highlights increasing industry focus on mechanism-based therapies capable of directly addressing the underlying causes of cancer cachexia.

Clinical Evidence Supporting Long-Term Weight and Muscle Recovery

Emerging clinical data are reinforcing the therapeutic potential of GDF-15 inhibition in managing cancer-related wasting disorders. Extended 12-month findings from the PROACC-1 Phase 2 clinical trial demonstrated that ponsegromab safely produced sustained gains in body weight and muscle mass among patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. During the open-label extension phase, patients achieved an average weight gain of 2.7 kilograms by week 24 and 4.4 kilograms by week 48. The therapy works by preventing GDF-15 from binding to GFRAL receptors in the brain, thereby interrupting signaling pathways that trigger appetite loss, metabolic imbalance, and progressive tissue wasting. These outcomes represent a significant advancement in the search for disease-modifying cachexia treatments and position GDF-15-targeted therapies among the most promising candidates for becoming the first FDA-approved pharmacological intervention specifically developed for cancer cachexia.

Multi-Modal Pharmacology Expanding Treatment Approaches

The cancer cachexia treatment landscape is increasingly embracing multi-modal therapeutic strategies designed to address the complex inflammatory and metabolic mechanisms underlying the condition. Clinical pipeline evaluations presented at major cachexia-focused scientific meetings highlighted growing interest in therapies capable of targeting both anabolic and catabolic pathways simultaneously. Actimed Therapeutics advanced its lead candidate, S-oxprenolol, into Phase II clinical development as an Anabolic-Catabolic Transforming Agent (ACTA). The compound is specifically engineered to counteract downstream muscle atrophy, improve functional performance, enhance overall survival potential, and restore metabolic balance in patients experiencing advanced tissue-wasting syndromes. This focus on integrated pharmacological intervention reflects a broader industry shift toward comprehensive cachexia management approaches that extend beyond symptom control to directly address muscle preservation, energy metabolism, and systemic inflammation.

Cancer Cachexia Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer Cachexia market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Endo, Inc., Helsinn Healthcare SA, Ono Pharmaceutical Co., Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC. The Cancer Cachexia market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer Cachexia industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer Cachexia Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer Cachexia companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer Cachexia markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer Cachexia Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer Cachexia industry include- Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Endo, Inc., Helsinn Healthcare SA, Ono Pharmaceutical Co., Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals PLC. The Cancer Cachexia market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer Cachexia Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer Cachexia market remains one of the strongest-performing segments in the country.
The US Cancer Cachexia Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer Cachexia market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer Cachexia industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer Cachexia markets

Canada's strong Cancer Cachexia sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer Cachexia market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer Cachexia Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer Cachexia market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer Cachexia population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer Cachexia industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer Cachexia market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer Cachexia sales through 2034

France Cancer Cachexia companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer Cachexia Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer Cachexia distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer Cachexia Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer Cachexia market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer Cachexia industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer Cachexia industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer Cachexia Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer Cachexia market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer Cachexia market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer Cachexia Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer Cachexia Market Segmentation

By Product
Progestogens
Corticosteroids
Combination Therapies
Anabolic Steroids & SARMs
Nutritional Supplements & Medical Foods
By Mechanism of Action
Appetite Stimulants
Myostatin Inhibitors
Ghrelin Receptor Agonists
Anti-inflammatory Agents
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By End-User
Cancer Treatment Centers
Hospitals
Homecare Settings
Palliative Care Facilities

Top Companies in Cancer Cachexia Industry

Pfizer Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd.
Endo, Inc.
Helsinn Healthcare SA
Ono Pharmaceutical Co., Ltd.
Fresenius Kabi AG
Hikma Pharmaceuticals PLC

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025